Pyxis Oncology, Inc. develops clinical-stage cancer therapeutics, with news centered on micvotabart pelidotin, or MICVO, an investigational antibody-drug conjugate targeting extradomain-B fibronectin in the tumor extracellular matrix. Company updates focus on MICVO in solid tumors, including recurrent or metastatic head and neck squamous cell carcinoma, and on monotherapy and pembrolizumab combination development.
Recurring developments include clinical and preclinical data presentations, translational research on MICVO’s mechanism of action, quarterly and annual financial results, corporate presentations, leadership changes, business development appointments, and capital actions tied to funding the company’s oncology pipeline.
Pyxis Oncology, Inc. (Nasdaq: PYXS) has priced its upsized initial public offering at $16.00 per share, raising approximately $168.0 million before expenses. The offering consists of 10,500,000 shares, all offered by Pyxis, with trading on the Nasdaq expected to commence on October 8, 2021. The offering is scheduled to close on October 13, 2021. Additionally, underwriters have a 30-day option to purchase up to 1,575,000 additional shares. Pyxis, focused on developing next-generation cancer therapeutics, aims to improve patient quality of life.